XERS - Company ID 0001867096
The table below shows Xeris Biopharma Holdings, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $83.13M | $74.38M | $71.54M | $60.12M | $54.27M | $48.06M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $8.78M | $7.48M | $8.05M | $7.75M | $5.89M | $5.76M |
Xeris Biopharma Holdings, Inc. reported annual revenue of $291.85M for fiscal year 2025. That is up 43.7% from $203.07M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $20.43M (FY 2020) to $291.85M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $53.14M |
| $46.46M |
| $44.39M |
| $44.02M |
| $44.97M |
| $39.99M |
| Operating income | $7.92M | $6.73M | $4.48M | -$3.09M | -$12.89M | -$8.19M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | -$3.32M | $749.00K |
| Net income | $2.23M | $621.00K | -$1.93M | -$9.22M | -$15.74M | -$15.01M |
| EPS (diluted) | $0.01 | $0.00 | -$0.01 | -$0.06 | -$0.11 | -$0.10 |